May 5, 2025 – TenNor’s new drug for H. pylori infection, Rifasutenizol (TNP-2198) made its debut at Digestive Disease Week (DDW) 2025 in San Diego, USA. A conference abstract titled “The Efficacy and Safety of Rifasutenizole (TNP-2198) Based Triple Regimen as First-Line Therapy For Helicobacter pylori Infection: A Multicenter, Double-Blind, Randomized, Controlled, Phase 3 Trial”, submitted by Professor Zhou Liya and Professor Song Zhiqiang from Peking University Third Hospital, along with Professor Wang Weihong from Peking University First Hospital, was selected for presentation at the Distinguished Abstract Plenary Session.

March 21, 2025 – TenNor Therapeutics announced the official initiation of a Phase II clinical trial for its first-in-class drug, TNP-2092, administered via intra-articular injection for the treatment of prosthetic joint infections (PJI). This significant milestone marks a crucial step forward for TenNor in addressing major unmet medical needs in the field of infectious diseases, offering new hope to millions of patients worldwide suffering from infections related to implanted medical devices.

February 26, 2025, Basel, Switzerland – TenNor Therapeutics presented its novel multi-targeting drug conjugation technology as a solution to antimicrobial resistance (AMR) problems at the 9th AMR Conference.

SUZHOU, China, Nov. 28, 2024 -- TenNor Therapeutics announced that it has entered an exclusive commercial partnership agreement with Grand Life Sciences (“GLS”) Group for rifasutenizol (TNP-2198) for the treatment of H. pylori infection. Under the agreement, TenNor licenses GLS’s wholly-owned subsidiary, Hangzhou Grand Biologic Pharmaceutical INC. ("Hangzhou Grand"), to exclusively commercialize and promote rifasutenizol in mainland China, Hong Kong and Macau.

SUZHOU, China, Nov. 18, 2024 -- TenNor Therapeutics, a clinical-stage company dedicated to developing novel therapies to address unmet needs in infectious diseases, announced today the successful completion of a phase III clinical trial of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The study met its primary endpoints, showing multiple advantages of rifasutenizol regimen compared with bismuth-containing quadruple therapy (BQT), the current standard of care.

October 18, 2024, Los Angels USA – Today, TenNor Therapeutics and its partners presented a series of research results on TNP-2092 (rifaquizinone) for the treatment of implantable medical device infections at the IDWeek 2024.

SUZHOU, China, Oct. 16, 2024 -- TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the initial closing of a Series E financing round for more than 300 million RMB. New investor AMR Action Fund joined Zhongshan Venture Capital and other existing investors in the round. The proceeds will be used to support the development and to seek regulatory approval in China of rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years.

July 2, 2024 – TenNor will present a series of posters on its investigational new drug rifaquizinone (TNP-2092) for the treatment of medical device infections at IDWeek 2024 to be held in Los Angeles, USA from October 16 to 20, 2024.